444 related articles for article (PubMed ID: 15916687)
1. The course of ADAMTS-13 activity and inhibitor titre in the treatment of thrombotic thrombocytopenic purpura with plasma exchange and vincristine.
Böhm M; Betz C; Miesbach W; Krause M; von Auer C; Geiger H; Scharrer I
Br J Haematol; 2005 Jun; 129(5):644-52. PubMed ID: 15916687
[TBL] [Abstract][Full Text] [Related]
2. Rituximab for treatment of refractory/relapsing thrombotic thrombocytopenic purpura (TTP).
Ahmad A; Aggarwal A; Sharma D; Dave HP; Kinsella V; Rick ME; Schechter GP
Am J Hematol; 2004 Oct; 77(2):171-6. PubMed ID: 15389904
[TBL] [Abstract][Full Text] [Related]
3. Remission in acute refractory and relapsing thrombotic thrombocytopenic purpura following rituximab is associated with a reduction in IgG antibodies to ADAMTS-13.
Scully M; Cohen H; Cavenagh J; Benjamin S; Starke R; Killick S; Mackie I; Machin SJ
Br J Haematol; 2007 Feb; 136(3):451-61. PubMed ID: 17233847
[TBL] [Abstract][Full Text] [Related]
4. Predicting response to plasma exchange in patients with thrombotic thrombocytopenic purpura with measurement of vWF-cleaving protease activity.
Mori Y; Wada H; Gabazza EC; Minami N; Nobori T; Shiku H; Yagi H; Ishizashi H; Matsumoto M; Fujimura Y
Transfusion; 2002 May; 42(5):572-80. PubMed ID: 12084165
[TBL] [Abstract][Full Text] [Related]
5. Clinical usefulness of a functional assay for the von Willebrand factor cleaving protease (ADAMTS 13) and its inhibitor in a patient with thrombotic thrombocytopenic purpura.
Rick ME; Austin H; Leitman SF; Krizek DM; Aronson DL
Am J Hematol; 2004 Feb; 75(2):96-100. PubMed ID: 14755376
[TBL] [Abstract][Full Text] [Related]
6. ADAMTS-13 may not predict disease or outcome in patients with Thrombotic Thrombocytopenic Purpura.
Rock G; Clark WF; Anderson D; Benny B; Sutton D; Leblond P; Sternbach M; Sontrop J;
Thromb Res; 2013 Apr; 131(4):308-12. PubMed ID: 23411128
[TBL] [Abstract][Full Text] [Related]
7. Acquired deficiency of von Willebrand factor-cleaving protease in a patient with thrombotic thrombocytopenic purpura.
Furlan M; Robles R; Solenthaler M; Lämmle B
Blood; 1998 Apr; 91(8):2839-46. PubMed ID: 9531594
[TBL] [Abstract][Full Text] [Related]
8. Recovery and half-life of von Willebrand factor-cleaving protease after plasma therapy in patients with thrombotic thrombocytopenic purpura.
Furlan M; Robles R; Morselli B; Sandoz P; Lämmle B
Thromb Haemost; 1999 Jan; 81(1):8-13. PubMed ID: 10348715
[TBL] [Abstract][Full Text] [Related]
9. Role of ADAMTS13 in the management of thrombotic microangiopathies including thrombotic thrombocytopenic purpura (TTP).
Shah N; Rutherford C; Matevosyan K; Shen YM; Sarode R
Br J Haematol; 2013 Nov; 163(4):514-9. PubMed ID: 24111495
[TBL] [Abstract][Full Text] [Related]
10. Rituximab for chronic recurring thrombotic thrombocytopenic purpura: a case report and review of the literature.
Yomtovian R; Niklinski W; Silver B; Sarode R; Tsai HM
Br J Haematol; 2004 Mar; 124(6):787-95. PubMed ID: 15009067
[TBL] [Abstract][Full Text] [Related]
11. [Clinical features and laboratory findings of thrombotic thrombocytopenic purpura associated with ticlopidine].
Yagi H
Rinsho Byori; 2005 Jul; 53(7):630-8. PubMed ID: 16104532
[TBL] [Abstract][Full Text] [Related]
12. [Activity loss of Von Willebrand factor cleaving protein (ADAMTS-13) is diagnostic for primary and pregnancy-related thrombotic thrombocytopenic purpura].
Hulstein JJ; Rison CN; Kappers-Klunne MC; Hene RJ; Franx A; de Groot PG; Brand A; Fijnheer R
Ned Tijdschr Geneeskd; 2004 Oct; 148(40):1972-6. PubMed ID: 15524133
[TBL] [Abstract][Full Text] [Related]
13. Antibodies to von Willebrand factor-cleaving protease in acute thrombotic thrombocytopenic purpura.
Tsai HM; Lian EC
N Engl J Med; 1998 Nov; 339(22):1585-94. PubMed ID: 9828246
[TBL] [Abstract][Full Text] [Related]
14. Hypersensitivity to plasma exchange in a patient with thrombotic thrombocytopenic purpura.
Lalmuanpuii J; Yalamanchili K; Fircanis S; Nelson JC
J Clin Apher; 2009; 24(1):18-20. PubMed ID: 19073012
[TBL] [Abstract][Full Text] [Related]
15. Von Willebrand factor, ADAMTS13, and thrombotic thrombocytopenic purpura.
Tsai HM
J Mol Med (Berl); 2002 Oct; 80(10):639-47. PubMed ID: 12395148
[TBL] [Abstract][Full Text] [Related]
16. Splenectomy in relapsing and plasma-refractory acquired thrombotic thrombocytopenic purpura.
Kremer Hovinga JA; Studt JD; Demarmels Biasiutti F; Solenthaler M; Alberio L; Zwicky C; Fontana S; Taleghani BM; Tobler A; Lämmle B
Haematologica; 2004 Mar; 89(3):320-4. PubMed ID: 15020271
[TBL] [Abstract][Full Text] [Related]
17. [Refractory thrombotic thrombocytopenic purpura successfully treated with a combination of rituximab and vincristine].
Kaneko H; Matsumoto M; Okamoto K; Chyonabayashi K; Hishizawa M; Watanabe M; Fujimura Y; Tsudo M
Rinsho Ketsueki; 2007 Feb; 48(2):144-7. PubMed ID: 17370643
[TBL] [Abstract][Full Text] [Related]
18. von Willebrand factor-cleaving protease in thrombotic thrombocytopenic purpura and the hemolytic-uremic syndrome.
Furlan M; Robles R; Galbusera M; Remuzzi G; Kyrle PA; Brenner B; Krause M; Scharrer I; Aumann V; Mittler U; Solenthaler M; Lämmle B
N Engl J Med; 1998 Nov; 339(22):1578-84. PubMed ID: 9828245
[TBL] [Abstract][Full Text] [Related]
19. Rituximab as pre-emptive treatment in patients with thrombotic thrombocytopenic purpura and evidence of anti-ADAMTS13 autoantibodies.
Bresin E; Gastoldi S; Daina E; Belotti D; Pogliani E; Perseghin P; Scalzulli PR; Paolini R; Marcenò R; Remuzzi G; Galbusera M
Thromb Haemost; 2009 Feb; 101(2):233-8. PubMed ID: 19190804
[TBL] [Abstract][Full Text] [Related]
20. Remission of chronic thrombotic thrombocytopenic purpura after treatment with cyclophosphamide and rituximab.
Zheng X; Pallera AM; Goodnough LT; Sadler JE; Blinder MA
Ann Intern Med; 2003 Jan; 138(2):105-8. PubMed ID: 12529092
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
